I found a little news worth repeating, a ten day old buy rating with review. Hope this is somewhat helpful. --- Affymetrix is the premier chip technology company in the
biotech sector. The company is on track to generate $100
million in sales in 1999, up form $54 million in 1998. Both
its gene expression chips and polymorphism chips will
contribute significantly. Although the company is still
expected to lose $1.00 in 1999, we estimate that it will
break even in 2000. Investors should also keep in mind that
part of the 1999 loss is due to the company's legal battles
with both Hyseq and Incyte Pharmaceuticals. Without the legal
bills, AFFX would lose about $0.50 in 1999.
AFFX continues to sign up customers for its DNA chips. Over a
dozen major pharmaceutical companies are now buying AFFX chips
. These include American Home Products, Eli Lilly, Hoffman La
Roche, Glaxo Wellcome, Merck, Novartis, Parke-Davis, Human
Genome Sciences, Pfizer, and, most recently, Hoechst Marion
Roussel and Rhone-Poulenc Rorer.
Affymetrix technology is also finding its way into the new
technology of microfluidics, which may revolutionize the
diagnostic industry over the next few years. ---
good investing,lnk. |
